SonoThera
Develops ultrasound-mediated nonviral genetic medicines
$125MSeries B
Role not disclosedJJ
Johnson & Johnson Innovation – JJDC
Activity from announced rounds
Activity in this selectionUnited States · Oct 23, 2026 · Jan 1, 2026
- Rounds participated in
- 5
- Confirmed lead rounds
- — 5 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $367M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionCereVasc
Develops minimally invasive eShunt System to treat communicating hydrocephalus and other neurological diseases
$85MSeries C
Role not disclosedTRex Bio
Develops precision immunoregulatory medicines based on tissue Treg biology
$50MUndisclosed
Role not disclosedResolve M Therapeutics
Builds pro-resolution platform for target ID and drug discovery for inflammatory diseases
UndisclosedUndisclosed
Role not disclosedEpiBiologics
Develops bispecific antibodies for targeted degradation of extracellular proteins.
$107MSeries B
Role not disclosed